FDA to Remove 12 Popular Peptides from the Category 2 Do Not Compound List Frier Levitt FDA Peptide Update 2026: Removal from Do Not Compound List and What It Means for Pharmacies Industry Update: Interim 503A and 503B Bulks Lists New Revisions Is BPC 157 Banned? Oral vs. Injectable Forms Explained The Peptide Landscape Is Shifting: What Secretary Kennedy's Joe Rogan Interview Could Mean for the Compounding Industry Frier Levitt FDA Peptide Regulation May Shift: What RFK Jr.'s Announcement Means for Compounding The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York